Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: A short-term randomized trial

American Journal of Kidney Diseases

Volumn 61, Issue 5, 2013, Pages 759-766

  Dwyer, Jamie P ^a   Sika, Mohammed ^a   Schulman, Gerald ^a   Chang, Ingrid J ^b   Anger, Michael ^b   Smith, Mark ^c   Kaplan, Mark ^d   Zeig, Steven ^e   Koury, Mark J ^a   Blumenthal, Samuel S ^f   Lewis, Julia B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Western Nephrology   (United States)

^c Kidney Care Associates   (United States)

^d Nephrology Associates   (United States)

^e Pines Clinical Research   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Clinical trial; end stage renal disease (ESRD); ferric citrate; phosphate binder

Indexed keywords

CALCIUM ACETATE; CARBONIC ACID; CHLORIDE; CINACALCET; FERRIC CITRATE; PHOSPHORUS; SEVELAMER; VITAMIN D;

ABNORMAL FECES COMPOSITION; ADULT; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STOOL DISCOLORATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876295026     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.11.041     Document Type: Article

References (9)

1. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 8 2004 2208 2218
2. W.G. Goodman, J. Goldin, B.D. Kuizon Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 20 2000 1478 1483
3. S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, F.K. Port Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 10 2001 2131 2138
4. G.M. Chertow, P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer, S.K. Burke Determinants of progressive vascular calcification in haemodialysis patients Nephrol Dial Transplant 19 6 2004 1489 1496
5. A.E. Ewence, M. Bootman, H.L. Roderick Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization Circ Res 103 5 2008 e28 e34
6. C.H. Hsu, S.R. Patel, E.W. Young New phosphate binding agents: ferric compounds J Am Soc Nephrol 10 6 1999 1274 1280
7. W.C. Yang, C.S. Yang, C.C. Hou, T.H. Wu, E.W. Young, C.H. Hsu An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate Nephrol Dial Transplant 17 2 2002 265 270
8. Sika M, Koury M, Smith M, et al. Evaluation of ferric citrate as a phosphate binder in dialysis patients requiring high doses of phosphate binders. ASN Renal Week; October 27-November 1, 2009; San Diego, California. Abstract TH-PO361.
9. A 58-week safety and efficacy trial of ferric citrate in patients with ESRD on dialysis http://clinicaltrials.gov/ct2/show/NCT01191255 Accessed April 1, 2012